Study the Role of Chfr in Tumorigenesis
Study the Role of Chfr in Tumorigenesis
批准号:
8967571
负责人:
Junjie Chen
金额:
$27.23万
依托单位国家:
美国
项目类别:
财政年份:
2006
资助国家:
美国
项目状态:
已结题
起止时间:
2006-07-01 至 2018-11-30
关键词:
AneuploidyCellsChromosomal InstabilityChromosomal StabilityChromosome StructuresChromosomesColon CarcinomaDNADevelopmentDown-RegulationEnsureEquilibriumFrequenciesFundingG1 PhaseG2 PhaseGenetic MaterialsHumanKnockout MiceLeadMLH1 geneMaintenanceMalignant NeoplasmsMetaphaseMicrosatellite InstabilityMismatch RepairMitosisMitoticMitotic CheckpointMolecularMusMutationPLK1 genePathway interactionsPhosphorylationPhosphotransferasesPlayProcessProphaseProteinsRegulationRoleS PhaseStressTestingTumor SuppressionTumor Suppressor ProteinsUp-RegulationWorkbasecancer typefunctional hypothalamic amenorrheahuman diseasein vivoinsightmouse modeloverexpressionprematurepreventresearch studytumortumor initiationtumorigenesisubiquitin-protein ligase
中文摘要
点击翻译按钮获取中文摘要
英文摘要
DESCRIPTION (provided by applicant): The genetic material DNA is packaged and organized into chromosomes in cells. Abnormal numbers of chromosomes or changes in chromosomal structures or organizations will cause human diseases including cancers. Many mitotic checkpoint pathways are evolved in the cell to maintain chromosomal stability. Studies in the last decade have highlighted the importance of spindle assembly checkpoint in the maintenance of chromosomal stability. While spindle checkpoint clearly plays a critical role in this process, mutations or dysregulations of spindle checkpoint components are not frequently observed in cancers, suggesting that tumor-associated instability could result from other deficiencies. One of these deficiencies is likely to be Chfr downregulation, which has been repeatedly observed in many types of cancers. Checkpoint protein with FHA and RING domains (Chfr) is involved in early mitotic checkpoint. It comprises of a RING domain and functions as an E3 ubiquitin ligase. During the last funding period, we have established Chfr knockout mice and demonstrated directly that Chfr acts as tumor suppressor. In addition, we showed that the major function of Chfr is to regulate the stability of several key mitotic proteins including Aurora A and PLK1. Our current working hypothesis is that Chfr normally acts throughout G1, S and G2 phases, but is specifically downregulated in mitosis. The function of Chfr is to prevent premature accumulation of many key mitotic regulators before the entry of mitosis. In the absence of Chfr and probably due to untimely upregulation of these Chfr substrates, cells would undergo abnormal mitotic transitions, which result in low frequency of chromosomal instability and thus promote tumorigenesis. Therefore, the identification of Chfr substrates and the understanding of Chfr downregulation in mitosis will reveal how Chfr normally act to prevent tumor initiation in vivo. We recently identified a potential mitotic kinase TOPK as a Chfr substrate. In addition, we demonstrated that Chfr deficiency greatly promoted tumorigenesis in MLH1-deficient mice, suggesting that chromosomal instability caused by Chfr deficiency may synergize with microsatellite instability caused by mismatch repair deficiency to facilitate tumorigenesis. Based on these preliminary studies, we propose to: (1) Study the functional interaction between Chfr and TOPK in mitosis; (2) Explore whether balanced regulation of TOPK
expression is critical for the maintenance of chromosomal stability and tumor suppression; (3) Determine whether chromosomal instability caused by Chfr downregulation cooperates with mismatch repair deficiency in tumor initiation.
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
DOI:
10.1158/0008-5472.can-14-2718
发表时间:
2015-05-01
期刊:
Cancer research
影响因子:
11.2
作者:
[Sorokin AV, Nair BC, Wei Y, Aziz KE, Evdokimova V, Hung MC, Chen J]
通讯作者:
Chen J
Deciphering pathways involved in topoisomerase II turnover
-
批准号:10552113
-
项目类别:
-
资助金额:$50.3万
-
财政年份:2023
-
负责人:Junjie Chen
-
依托单位:
Elucidating mechanisms underlying replication checkpoint control
-
批准号:10620981
-
项目类别:
-
资助金额:$49.94万
-
财政年份:2023
-
负责人:Junjie Chen
-
依托单位:
Exploring DNA damage response pathways as targets for cancer therapy
-
批准号:10515484
-
项目类别:
-
资助金额:$58.34万
-
财政年份:2022
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:9883637
-
项目类别:
-
资助金额:$43.64万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:10087898
-
项目类别:
-
资助金额:$43.64万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Novel regulations of DNA damage repair
-
批准号:9326453
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:10311996
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Project 4: Coordinating Nucleolytic Pathways During Crosslink Repair
-
批准号:9148677
-
项目类别:
-
资助金额:$35.43万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:9206732
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Define redundant functions of H2AX and NBS1 in DNA repair
-
批准号:10053713
-
项目类别:
-
资助金额:$36.6万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
53BP1-dependent pathway in DNA repair
-
批准号:9763542
-
项目类别:
-
资助金额:$35.5万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
53BP1-dependent pathway in DNA repair
-
批准号:10404655
-
项目类别:
-
资助金额:$35.87万
-
财政年份:2017
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8234219
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8467691
-
项目类别:
-
资助金额:$30.82万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8628642
-
项目类别:
-
资助金额:$31.8万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
Fanconi anemia pathway in DNA damage repair
-
批准号:8826053
-
项目类别:
-
资助金额:$32.79万
-
财政年份:2012
-
负责人:Junjie Chen
-
依托单位:
MRI BIOMARKERS OF ANGIOGENESIS AND CELL INJURY IN RETINOPATHY OF PREMATURITY
-
批准号:7577530
-
项目类别:
-
资助金额:$19.0万
-
财政年份:2008
-
负责人:Junjie Chen
-
依托单位:
MRI BIOMARKERS OF ANGIOGENESIS AND CELL INJURY IN RETINOPATHY OF PREMATURITY
-
批准号:7450075
-
项目类别:
-
资助金额:$21.76万
-
财政年份:2008
-
负责人:Junjie Chen
-
依托单位:
The Role of CHFR in Tumorigenesis and Paclitaxel-Sensitivity in Breast Cancer
-
批准号:7737070
-
项目类别:
-
资助金额:$20.67万
-
财政年份:2008
-
负责人:Junjie Chen
-
依托单位:
Study the Role of Chfr in Tumorigenesis
-
批准号:7806610
-
项目类别:
-
资助金额:$26.54万
-
财政年份:2006
-
负责人:Junjie Chen
-
依托单位:
国内基金
海外基金
登录
查看更多内容
分化肌细胞脱细胞ECM-cells sheet 3D
支架构建及其促进容积性肌组织缺损再
生修复应用及机制研究
-
批准号:
-
项目类别:省市级项目
-
资助金额:10.0万元
-
批准年份:2025
-
负责人:肖将尉
-
依托单位:
CAFs-TAMs-tumor cells调控在HRHPV感染致癌中的作用机制研究及AI可追溯预测模型建立
-
批准号:82072862
-
项目类别:面上项目
-
资助金额:56.0万元
-
批准年份:2020
-
负责人:徐云升
-
依托单位:
S100A8/A9--Myeloid cells特异性可溶性表氧化物水解酶(sEH)基因敲除改善胰岛素抵抗的新靶点
-
批准号:82070825
-
项目类别:面上项目
-
资助金额:53.0万元
-
批准年份:2020
-
负责人:徐西振
-
依托单位:
Leader cells通过CCL5调控糖酵解及基质硬度促进结直肠癌集体侵袭的 作用机制
-
批准号:81903002
-
项目类别:青年科学基金项目
-
资助金额:20.5万元
-
批准年份:2019
-
负责人:王斐斐
-
依托单位:
HA/CD44在乳腺癌转移“先导细胞”(leader cells)侵袭中的作用及机制研究
-
批准号:81402419
-
项目类别:青年科学基金项目
-
资助金额:23.0万元
-
批准年份:2014
-
负责人:杨翠霞
-
依托单位:
双模式编码的慢病毒载体转染C6 Glioma Cells的影像学研究
-
批准号:81271563
-
项目类别:面上项目
-
资助金额:60.0万元
-
批准年份:2012
-
负责人:陈正光
-
依托单位:
树突状细胞(Dendritic cells,DCs)介导的黏膜免疫对猪轮状病毒(PRV)感染的分子作用机制研究
-
批准号:31272541
-
项目类别:面上项目
-
资助金额:82.0万元
-
批准年份:2012
-
负责人:王春凤
-
依托单位:
MTA2在睾丸支持细胞(Sertoli cells)中的功能和机制研究
-
批准号:31271248
-
项目类别:面上项目
-
资助金额:80.0万元
-
批准年份:2012
-
负责人:李伟
-
依托单位:
无外源性基因iPS cells向肠细胞分化及对肠损伤的修复
-
批准号:81160050
-
项目类别:地区科学基金项目
-
资助金额:49.0万元
-
批准年份:2011
-
负责人:邵立健
-
依托单位: